Lilly’s Tirzepatide Shows Benefit In Heart Failure, Including Outcomes
Executive Summary
Lilly is the first to demonstrate a benefit on heart failure outcomes with an incretin, even though rival Novo Nordisk already filed heart failure data for Wegovy with the US FDA.